Scleroderma Renal Crisis

Scleroderma renal crisis (SRC) is an infrequent complication of a rare disease. To date, many aspects of the pathophysiology of SRC are still mysterious. Since SRC biopsies are not frequently encountered in practice, our understanding of the spectrum of histologic changes is derived from a combination of a limited personal experience and data obtained from several relatively small pathologic studies. This book chapter will be devoted to discuss the pathophysiology and the histologic manifestations of SRC and will cover the most important aspects of clinical and laboratory findings as well as treatment of SRC. Systemic sclerosis (SSc) is a chronic systemic autoimmune disease characterized by excess collagen production. According to the extent of cutaneous sclerosis, SSc can be classified as either diffuse cutaneous (dc) or limited cutaneous (lc) variant (Sakkas, 2005). Many studies have been conducted to explore the pathogenesis of SSc. Activation of T-cells, B-cells and macrophages have been described and linked to the development and progression of fibrosis (Sakkas, Chikanza, & Platsoucas, 2006). Activated T-cells, mainly T helper lymphocyte type-2 (TH-2), are associated with increased IL-4 and IL-13 production and collagen accumulation. Activated B-cells produce autoantibodies that can facilitate transformation of fibroblasts into more fibrotic phenotypes while activated macrophages can accumulate in the perivascular spaces to produce transforming growth factor-B and platelet derived growth factor, which can also promote fibrosis. In addition to collagen accumulation, endothelial cell injury appears to play a central role in the pathogenesis of SSc. Increased permeability of the nail fold capillaries (Bollinger, Jager, & Siegenthaler, 1986) and increased endothelial apoptosis (Sgonc et al., 1996)have been described in SSc patients. Endothelial cell injury in SSc may be triggered by anti-endothelial antibody (Worda et al., 2003), cytokines (Kahaleh, 2004), complement abnormalities (Venneker, van den Hoogen, Boerbooms, Bos, & Asghar, 1994) and/or cellular cytotoxicity (Sgonc et al., 2000). Scleroderma renal crisis (SRC) can complicate the course of up to 10-20% of patients with SSc. SRC is most commonly encountered in patients with dcSSc; however, it can still occur in patients with lcSSc(Sugimoto, Sanada, & Kashiwagi, 2008; Sugimoto et al., 2006) and even in patients with no significant dermal sclerosis, termed systemic sclerosis sine scleroderma (ssSSc) (Gonzalez, Schmulbach, & Bastani, 1994). Compared to SSc, much less is known

[1]  T. Radstake Systemic Sclerosis - An Update on the Aberrant Immune System and Clinical Features , 2012 .

[2]  L. Mouthon,et al.  Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis , 2011, Clinical reviews in allergy & immunology.

[3]  M. Haas,et al.  C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. , 2011, Clinical nephrology.

[4]  R. Domsic,et al.  Scleroderma Renal Crisis: A Pathology Perspective , 2010, International journal of rheumatology.

[5]  M. Mayes,et al.  Association of RNA Polymerase III Antibodies with Scleroderma Renal Crisis , 2010, The Journal of Rheumatology.

[6]  Jianzhu Chen,et al.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis , 2010, Science China Life Sciences.

[7]  P. Halloran,et al.  Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection , 2010, Current opinion in organ transplantation.

[8]  Toshiyuki Yamamoto Animal model of systemic sclerosis , 2010, The Journal of dermatology.

[9]  C. Bellamy,et al.  Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  C. Obasaju,et al.  Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV , 2009, Clinical lung cancer.

[11]  K. Isobe,et al.  Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. , 2009, The Journal of investigative dermatology.

[12]  T. Medsger,et al.  Anti-U3 RNP autoantibodies in systemic sclerosis. , 2009, Arthritis and rheumatism.

[13]  R. Domsic,et al.  Renal biopsy findings predicting outcome in scleroderma renal crisis. , 2009, Human pathology.

[14]  U. Müller-Ladner,et al.  Renal complications and scleroderma renal crisis. , 2006, Rheumatology.

[15]  C. K. Jacob,et al.  Scleroderma with crescentic glomerulonephritis: a case report , 2008, Journal of medical case reports.

[16]  T. Sugimoto,et al.  IS SCLERODERMA RENAL CRISIS WITH ANTI‐CENTROMERE ANTIBODY‐POSITIVE LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OVERLOOKED IN PATIENTS WITH HYPERTENSION AND/OR RENAL DYSFUNCTION? , 2008, Nephrology.

[17]  L. Mouthon,et al.  Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients , 2007, Annals of the rheumatic diseases.

[18]  D. Greiner,et al.  Humanized SCID mouse models for biomedical research. , 2008, Current topics in microbiology and immunology.

[19]  T. Uzu,et al.  [Case of scleroderma with rapid progressive glomerulonephritis associated with both MPO-ANCA and anti-GBM antibodies]. , 2008, Nihon Jinzo Gakkai shi.

[20]  C. Denton,et al.  Scleroderma renal crisis: patient characteristics and long-term outcomes. , 2007, QJM : monthly journal of the Association of Physicians.

[21]  I. Chikanza,et al.  Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis , 2006, Nature Clinical Practice Rheumatology.

[22]  K. Danno,et al.  Scleroderma renal crisis in a patient with anticentromere antibody-positive limited cutaneous systemic sclerosis , 2006, Modern rheumatology.

[23]  D. Kamen,et al.  Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma--a different kind of renal crisis. , 2006, The Journal of rheumatology.

[24]  B. Iványi,et al.  Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts , 2006, Nature Clinical Practice Nephrology.

[25]  W. Wallace,et al.  Predictors and Risk Factors for Recurrent Scleroderma Renal Crisis in the Kidney Allograft: Case Report and Review of the Literature , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  D. Rush,et al.  Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  L. Sakkas New developments in the pathogenesis of systemic sclerosis , 2005, Autoimmunity.

[28]  Kahaleh Mb Vascular involvement in systemic sclerosis (SSc). , 2004 .

[29]  M. Kahaleh Vascular involvement in systemic sclerosis (SSc). , 2004, Clinical and experimental rheumatology.

[30]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. VI: Evaluation of bleomycin-induced skin sclerosis in nude mice , 2004, Archives of Dermatological Research.

[31]  M. Gershwin,et al.  In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. , 2003, Arthritis and rheumatism.

[32]  M. Fishbein,et al.  Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  J. Walker,et al.  Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment , 2003, Internal medicine journal.

[34]  A. Flahault,et al.  Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  S. Bombardieri,et al.  Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients , 2002, Medicine.

[36]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. , 2002, Clinical immunology.

[37]  K. Nishioka,et al.  Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. , 2001, The Journal of investigative dermatology.

[38]  R. Carey,et al.  Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP , 2001, Hypertension.

[39]  T. Medsger,et al.  Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. , 2001, Arthritis and rheumatism.

[40]  N. Sepp,et al.  Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. , 2000, Arthritis and rheumatism.

[41]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[42]  T. Medsger,et al.  Long-Term Outcomes of Scleroderma Renal Crisis , 2000, Annals of Internal Medicine.

[43]  G. Wick,et al.  Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). , 2000, Journal of autoimmunity.

[44]  N. Lertprasertsuke,et al.  Quantitative estimation of renin‐containing cells in the juxtaglomerular apparatus in Bartter’s and pseudo‐Bartter’s syndromes , 2000, Pathology international.

[45]  K. Nishioka,et al.  Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. , 1999, The Journal of rheumatology.

[46]  H. Spiera,et al.  Recurrence of scleroderma in a renal allograft from an identical twin sister. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. , 1999, The Journal of investigative dermatology.

[48]  R. Kasukawa,et al.  Immunohistological Study of Endothelin-1 and Endothelin-A and B Receptors in Two Patients with Scleroderma Renal Crisis , 1999, Clinical Rheumatology.

[49]  R. Safadi,et al.  Normotensive scleroderma renal crisis: case report and review of the literature. , 1998, Renal failure.

[50]  J. Barnes,et al.  Failure of losartan to control blood pressure in scleroderma renal crisis , 1997, The Lancet.

[51]  M. Gershwin,et al.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. , 1996, The Journal of clinical investigation.

[52]  R. Scorza,et al.  Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. , 1996, Arthritis and rheumatism.

[53]  C. Ferri,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.

[54]  S. Patel,et al.  Favourable Outcome of Scleroderma Renal Crisis , 1996, Journal of the Royal Society of Medicine.

[55]  V. Steen Scleroderma renal crisis. , 2003, Rheumatic diseases clinics of North America.

[56]  V. Steen,et al.  Autoantibodies in systemic sclerosis. , 1996, Bulletin on the rheumatic diseases.

[57]  M. Akizuki,et al.  Massive pericardial effusion in scleroderma: a review of five cases. , 1995, British journal of rheumatology.

[58]  F. V. D. van den Hoogen,et al.  Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[59]  V. Steen,et al.  Renal Involvement in Systemic Sclerosis , 2019, New Insights into Systemic Sclerosis [Working Title].

[60]  B. Bastani,et al.  Scleroderma renal crisis with minimal skin involvement and no serologic evidence of systemic sclerosis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[61]  T. Medsger,et al.  Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis , 1993, Annals of Internal Medicine.

[62]  Gohn Dc,et al.  Polymorphic ventricular tachycardia (Torsade de Pointes) associated with the use of probucol. , 1992 .

[63]  S. Ballou,et al.  Reversible scleroderma renal crisis after cocaine use. , 1992, The New England journal of medicine.

[64]  J. Costantino,et al.  Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. , 1990, Annals of internal medicine.

[65]  T. Medsger,et al.  Normotensive renal failure in systemic sclerosis. , 1989, Arthritis and rheumatism.

[66]  M. Yanagisawa,et al.  A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. , 1989, The Journal of biological chemistry.

[67]  Y. Bar-Khayim,et al.  Scleroderma renal crisis without hypertension. , 1989, The Journal of rheumatology.

[68]  Y. Hirata Endothelin‐1 Receptors in Cultured Vascular Smooth Muscle Cells and Cardiocytes of Rats , 1989, Journal of cardiovascular pharmacology.

[69]  F. Silva,et al.  Electron microscopic study of medical diseases of the kidney: update--1988. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[70]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[71]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[72]  K. Hayashi,et al.  Disseminated intravascular coagulation (DIC). Immunohistochemical study of fibrin-related materials (FRMs) in renal tissues. , 2008, Acta pathologica japonica.

[73]  W. Siegenthaler,et al.  Microangiopathy of progressive systemic sclerosis. Evaluation by dynamic fluorescence videomicroscopy. , 1986, Archives of internal medicine.

[74]  T. Medsger,et al.  Systemic sclerosis (scleroderma) and multiple sclerosis. , 1986, Arthritis and rheumatism.

[75]  T. Medsger,et al.  Factors predicting development of renal involvement in progressive systemic sclerosis. , 1984, The American journal of medicine.

[76]  R. Thurm,et al.  Captopril in the treatment of scleroderma renal crisis. , 1984, Archives of internal medicine.

[77]  T. Medsger,et al.  Hypertension and Renal Failure (Scleroderma Renal Crisis) in Progressive Systemic Sclerosis: REVIEW OF A 25‐YEAR EXPERIENCE WITH 68 CASES , 1983, Medicine.

[78]  J. Mountz,et al.  Bleomycin‐induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma , 1983, The British journal of dermatology.

[79]  Immunology,et al.  Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma) , 1981, The Journal of experimental medicine.

[80]  H. Paulus,et al.  Clinical course of patients with scleroderma renal crisis treated with captopril. , 1981, Nephron.

[81]  J. Laragh,et al.  Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. , 1979, The New England journal of medicine.

[82]  S. Guggenheim,et al.  The kidney in progressive systemic sclerosis: a prospective study. , 1978, Annals of internal medicine.

[83]  P. Feig,et al.  Control of hypertension and reversal of renal failure in scleroderma. , 1978, The New England journal of medicine.

[84]  T. Cavallo,et al.  Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma). , 1978, The American journal of pathology.

[85]  H. Seigler,et al.  Apparent recurrence of progressive systemic sclerosis in a renal allograft. , 1976, JAMA.

[86]  McCoy Rc,et al.  The kidney in progressive systemic sclerosis: immunohistochemical and antibody elution studies. , 1976 .

[87]  P. Pepe,et al.  The kidney in progressive systemic sclerosis: immunohistochemical and antibody elution studies. , 1976, Laboratory investigation; a journal of technical methods and pathology.

[88]  E. Leroy,et al.  Pericardial disease in scleroderma (systemic sclerosis). , 1974, The American journal of medicine.

[89]  W. Cook,et al.  Renal Scleroderma and Pregnancy , 1974, Obstetrics and gynecology.

[90]  P. Cannon,et al.  THE RELATIONSHIP OF HYPERTENSION AND RENAL FAILURE IN SCLERODERMA (PROGRESSIVE SYSTEMIC SCLEROSIS) TO STRUCTURAL AND FUNCTIONAL ABNORMALITIES OF THE RENAL CORTICAL CIRCULATION , 1974, Medicine.

[91]  R. R. Robinson,et al.  Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated acute renal failure. , 1974, The American journal of medicine.

[92]  W. R. Salyer,et al.  Scleroderma and microangiopathic hemolytic anemia. , 1973, Annals of internal medicine.

[93]  A. Masi,et al.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. , 1971, Annals of internal medicine.

[94]  A. Barnett,et al.  RENAL IMMUNE DEPOSITS IN SCLERODERMA , 1971, Pathology.

[95]  C. Jiménez Díaz,et al.  [Renal lesions in scleroderma]. , 1963, Revista clinica espanola.

[96]  E. Fisher,et al.  Pathologic observations concerning the kidney in progressive systemic sclerosis. , 1958, A.M.A. archives of pathology.

[97]  Rodnan Gp,et al.  Pathologic observations concerning the kidney in progressive systemic sclerosis. , 1958 .

[98]  J. G. Sharnoff,et al.  Cortisone-treated scleroderma; report of a case with autopsy findings. , 1951, Journal of the American Medical Association.